 |
 |
 |  |
|
Home |
 |
 |
 |
| Should we treat or not??? |
| Performace Status |
| Antiemetics |
| Growth Factors |
| Calculations |
| Chemo Precautions |
| TOXICITY CRITERIA |
| Antidepressants |
| Chemoprotection |
| MESNA |
| Dexrazoxane |
| Radioprotectants |
| Hypercalcemia of malignancy |
| Mucositis |
| Neutropenic Fever |
| Palliative Care |
| Radiation Oncology |
| <<<<<<<<<>>>>>>>>> |
| ALL |
| AML |
| Anal |
| Bladder Cancer |
| Brain Cancer |
| Breast (risk category) |
| Breast (adjuvant) |
| Breast (metastatic) |
| Breast (Xeloda) |
| Breast (hormonal) |
| Breast Cancer Genetics |
| Carcinoid |
| CLL |
| CML |
| COLON CANCER |
| Endometrial |
| Esophagous |
| Gastric |
| Gestational Trophoblastic Disease |
| Germ Cell (Ovary) |
| Hairy Cell Leukemia |
| Head/Neck |
| Head/Neck: ChemoRT abstracts |
| Head/Neck: Larynx |
| Head/Neck:Nasopharyngeal |
| Hodgkins |
| Islet Cell Tumors |
| Kidney |
| Liver |
| LUNG, NSC |
| Stage III Unresectable NSC Lung Cancer |
| Lung, SC |
| Lymphoma, Aggressive |
| Lymphoma, AIDS |
| Lymphoma, Burkitts |
| Lymphoma, CNS |
| Lymphoma, Cutaneous |
| Lymphoma, Indolent |
| Lymphoma, MALT |
| Lymphoma, Mantle cell |
| Lymphoma, Mediastinal B-Cell |
| Lymphoma, Refractory NHL |
| Melanoma |
| Mesothelioma |
| Multiple Myeloma |
| MDS |
| NHL |
| Ovarian |
| Pancreas |
| Prostate |
| Prostate (Hormonal) |
| Rectal Cancer |
| Sarcoma |
| Sarcoma, Ewing's |
| Sarcoma, Osteogenic |
| Skeletal Metastasis |
| Testicular Cancer |
| Thymoma |
| Thyroid Cancer |
| Waldenstrom's |
| Unknown Primary |
| <<<<<<<<<>>>>>>>>> |
| Molecular Genetics |
| Oncogenes, the list! |
| Immunoperoxidase stains |
| Tumor Markers |
| Bleomycin |
| Cisplatin |
| Etoposide |
| Ifosfamide |
| Methotrexate |
| Temazolamide |
| Mechanism of Action |
| Dose Modifications (Renal) |
| Dose Modifications (hepatic) |
| MDR |
|
|  |
|
 |
|
Colon Cancer, Adjuvant Colon Cancer, metastatic
|
 |
|
***ADJUVANT COLON CANCER: 5FU + Leucovorin ---- Low-dose 5FU 425 mg/m2/d IV bolus DAYS 1-5 Leucovorin 20 mg/m2 IV bolus DAYS 1-5 immediately before 5FU Repeat cycle at 4 weeks, 8 weeks, then Q5weeks JCO 7:1407-1418, 1989 --------------------------------------------------------------------------- Adjuvant High Dose Leucovorin + 5FU Leucovorin 500 mg/m2 IV over 2 hours Q week X 6 weeks 5 FU 500 mg/m2 IV over 1 hour after the start of leucovorin Qweek X 6 weeks Repeat Q8weeks X 6 cycles Proc Am Soc Clin Oncol 15:205, 1996 --------------------------------------------------------------------------- Advanced Colorectal CA: Bimonthly high-dose leucovorin & 5FU bolus plus CI (LV5FU2) LV 200 mg/m2 as a 2-hour infusion followed by bolus 5-FU 400 mg/m2 and 22-hour infusion 5FU 600 mg/m2 for 2 consecutive days every 2 weeks REF: JCO 15:808, 1997 LV5FU2 was superior to 5FU/LV monthly 5-day regimen in terms of RR, PFS, toxicity but not OS RR: 32.6% vs 14.5% P = .0004 PFS: 27.6 wks vs 22 wks P = .0012 Grade 3-4: 11.1% vs 22.9% P = .0004 OS: 56.8 weeks vs 62 weeks P = .067 ___________________________________________ ***METASTATIC COLON CANCER: 5FU+Leucovorin+Irinotecan Qweek X 4 (of 6 weeks) IRINOTECAN 125 mg/m2 LEUCOVORIN 20 mg/m2 bolus 5FU 500 mg/m2 bolus Proc Am Soc Clin Oncol 18:2333a, 1999 --------------------------------------------------------------------------- IRINOTECAN Single agent: IRINOTECAN 350 mg/m2 Q3weeks ___________________________________________
|
 |
|
|  |
|
TOXICITIES: IRIONOTECAN: Diarrhea- use lopramide 4 mg loading dose followed by 2 mg Q2hours until diarrhea stops for at least 12 hours |
 |
 |
|
. |
|
|